Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis

被引:30
作者
Alsaleh, Khalid A. [1 ]
Al-Nasser, Sami M. A. [1 ]
Bates, Shannon M. [1 ]
Patel, Ameen [1 ]
Warkentin, Theodore E. [1 ,2 ]
Arnold, Donald M. [1 ]
机构
[1] McMaster Univ, Dept Med, Michael G DeGroote Sch Med, Hamilton, ON, Canada
[2] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
关键词
D O I
10.1002/ajh.21273
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenia (HIT) is a prothrombotic condition caused by platelet-activating antibodies that react with platelet factor 4 (PF4)/heparin complexes. Delayed-onset HIT occurs after heparin is stopped. Fondaparinux, a synthetic pentasaccharide, is thought to be a safe alternative anticoagulant in HIT. We describe a patient with delayed-onset HIT triggered by low-molecular-weight heparin (LMWH) which occurred during fondaparinux prophylaxis and which was complicated by microangiopathic hemolytic anemia. Patient serum contained high-titer anti-PF4/heparin antibodies demonstrating heparin-dependent platelet activation with serial dilutions. Confirmed delayed-onset HIT with LMWH has not been previously reported. Low dose fondaparinux does not necessarily prevent thrombotic complications of HIT. Am. J. Hematol. 83:876-878, 2008. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:876 / 878
页数:3
相关论文
共 21 条
[1]   Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings [J].
Greinacher, A. ;
Alban, S. ;
Omer-Adam, M. A. ;
Weitschies, W. ;
Warkentin, T. E. .
THROMBOSIS RESEARCH, 2008, 122 (02) :211-220
[2]   Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies [J].
Greinacher, Andreas ;
Gopinadhan, Manesh ;
Gunther, Jens-Uwe ;
Omer-Adam, Mahmoud A. ;
Strobel, Ulrike ;
Warkentin, Theodore E. ;
Papastavrou, Georg ;
Weitschies, Werner ;
Helm, Christiane A. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (10) :2386-2393
[3]  
Harenberg J, 2004, HAEMATOLOGICA, V89, P1017
[4]  
Jackson Mark R, 2006, Vasc Endovascular Surg, V40, P67, DOI 10.1177/153857440604000109
[5]   Fondaparinux: A potential new therapy for HIT [J].
Kuo, KHM ;
Kovacs, MJ .
HEMATOLOGY, 2005, 10 (04) :271-275
[6]   Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia [J].
Lobo, Bob ;
Finch, Christopher ;
Howard, Amanda ;
Minhas, Sohail .
THROMBOSIS AND HAEMOSTASIS, 2008, 99 (01) :208-214
[7]   Risk for heparin-induced thrombocytopenia. with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis [J].
Martel, N ;
Lee, J ;
Wells, PS .
BLOOD, 2005, 106 (08) :2710-2715
[8]   Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications [J].
Rauova, L ;
Zhai, L ;
Kowalska, MA ;
Arepally, GM ;
Cines, DB ;
Poncz, M .
BLOOD, 2006, 107 (06) :2346-2353
[9]   Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin "flushes" [J].
Refaai, Majed A. ;
Warkentin, Theodore E. ;
Axelson, Michael ;
Matevosyan, Karen ;
Sarode, Ravindra .
THROMBOSIS AND HAEMOSTASIS, 2007, 98 (05) :1139-1140
[10]   Delayed-onset heparin-induced thrombocytopenia [J].
Rice, L ;
Attisha, WK ;
Drexler, A ;
Francis, JL .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (03) :210-215